Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Positive and statistically significant topline data from the pivotal LOGICS study of Recorlev

Sep. 9, 2020

Enterin identifies new PTP-1B inhibitors

Sep. 8, 2020

mTOR-targeting metabolite discovered

Sep. 8, 2020

BIO89-100 enters phase II trial for severe hypertriglyceridemia

Sep. 4, 2020

New therapeutic target for blood sugar control identified

Sep. 3, 2020

Engineered brown fat cells improve blood sugar control

Sep. 3, 2020

FDA approves Sogroya for adult growth hormone deficiency

Sep. 2, 2020

AM-535 demonstrates efficacy in model of diet-induced hyperammonemia

Sep. 2, 2020

Additional interim results presented from proof-of-concept study of OTL-203 for MPS-I

Sep. 2, 2020

TRILOGY 2 study of CaPre in severe hypertriglyceridemia does not meet primary endpoint

Aug. 31, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...